...
首页> 外文期刊>Ophthalmology >Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b
【24h】

Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b

机译:局部干扰素Alfa-2b治疗结膜和角膜上皮内瘤变的长期随访

获取原文
获取原文并翻译 | 示例

摘要

To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b. Retrospective, noncomparative, interventional case series. Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved.Patients' charts and clinical photographs were reviewed, and data were analyzed. All eyes were monitored for the possibility of recurrence with a minimum of 1 -year follow-up from the time of documented clinical resolution. Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%). One of the 28 eyes treated (3.6%) had only a partial response to treatment. For the 27 eyes with complete response, resolution occurred after a median of 2.0 months (range, 10 days-15 months). Eyes were treated for a median of 3.2 months (range, 1-15). Median follow-up after clinical resolution (tumor-free period) was 42.4 months (range, 14-89). One eye of the 27 analyzed (3.7%) experienced a recurrence. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%). In all cases, there was total resolution of the side effects within 1 month after cessation of the medication.In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects. Ophthalmology#
机译:评估局部干扰素α-2b治疗结膜和角膜上皮内瘤变(CIN)的长期复发率(> 1年)。回顾性,非比较性,介入性病例系列。在1997年4月至2005年6月期间对来自2个机构的26例患者的28眼进行了治疗,使用局部干扰素al-2b每天滴入CIN病变的次数为每天4次,直至达到临床分辨率为止。分析。从有案可查的临床解决方案开始,至少随访1年,监测所有眼睛的复发可能性。在治疗的28只眼中有27只(96.4%)实现了CIN病变的完全临床解决。治疗的28只眼中有一只(3.6%)对治疗仅部分反应。对于完全反应的27眼,中位数为2.0个月(范围为10天至15个月)后才解决。眼睛接受中位治疗3.2个月(范围1-15)。临床解决后(无肿瘤期)的中位随访时间为42.4个月(范围14-89)。在分析的27眼中有一只眼(3.7%)复发了。治疗的副作用仅限于3例(12%)的轻度结膜充血和滤泡性结膜炎。在所有情况下,停止用药后1个月内总的副作用得以缓解。在观察到> 1年的CIN病变的这一组患者中,局部干扰素alfa-2b可有效治疗自我限制最小的病变副作用。眼科#

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号